Company Profile

Navan Technologies Inc
Profile last edited on: 9/29/20      CAGE: 7Y3L6      UEI: LNQMJQ31BN31

Business Identifier: Novel non-viral delivery platform radically to accelerate genetic engineering of human primary cells.
Year Founded
2016
First Award
2016
Latest Award
2018
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

329 Oyster Point Boulevard 3rd Floor
South San Francisco, CA 94080
   (904) 402-7442
   info@navanbio.com
   www.navanbio.com~navan-tech.com/
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

Part of the JLab endeavors in San Carlos CA, NAVAN Technologies describe what they do as engineering pipelines into cells - offering delivery of the User's chosen cargo into any cell. The firm is enabling next generation cellular engineering for therapeutics and regnerative medicine through seamless, direct delivery of any cargo into any cell without perturbing cell function or viability in the process.Management's vision is to facilitate cell and gene therapies at the point of care. With the capability to streamline new therapy development and robust performance at scale, NanoStraws significantly decrease costs, making clinical applications affordable and accessible. Based on technology exclusively licensed from Stanford University, the firm's novel, non-viral NanoStraw platform, technology provides direct intracellular access into hard-to-transfect human primary cells for the efficient delivery of any cargo into any cell. By using a physical, non-perturbative delivery mechanism (Nano-injection) for cell transformation, many of the challenges presented by viral-based cell manufacturing technology provides direct intracellular access into hard-to-transfect human primary cells for the efficient delivery of any cargo into any cell. By using a physical, non-perturbative delivery mechanism (Nano-injection) for cell transformation, many of the challenges presented by viral-based cell manufacturing are avoided while preserving cell function and viability.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 2 NSF $975,000
Project Title: Nanostraw-mediated Immune Cell Reprogramming

Key People / Management

  Michael Nowak -- CEO

  Chris Rehse -- President & Co Founder

  Sarah Boyatzis -- Chief of Staff

  Craig Garner -- Co-Founder

  Martin Hjort -- Chief Technology Officer

  Susan Johnson -- Senior Scientist – Immuno-oncology

  Sergio Leal-Ortiz -- Co-Founder & Chief Scientific Officer

  Nicholas Melosh -- Co-PI

  Nicholas A Melosh -- Co-Founder

  Canh Nguyen -- NanoStraw Engineer

  Chris Rehse -- Co-Founder

  Jose Rivera -- Laboratory Technician

  Hannes Voßfeldt -- Senior Scientist

Company News

There are no news available.